🚀 Gate Fun Chinese Meme Fever Keeps Rising!
Create, launch, and trade your own Meme tokens to share a 3,000 GT!
Post your Meme on Gate Square for a chance to win $600 in sharing rewards!
A total prize pool of $3,600 awaits all creative Meme masters 💥
🚀 Launch now: https://web3.gate.com/gatefun?tab=explore
🏆 Square Sharing Prizes:
1️⃣ Top Creator by Market Cap (1): $200 Futures Voucher + Gate X RedBull Backpack + Honor Poster
2️⃣ Most Popular Creator (1): $200 Futures Voucher + Gate X RedBull Backpack + Honor Poster
3️⃣ Lucky Participants (10): $20 Futures Voucher (for high-quality posts)
O
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.